Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 812 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Assessment, Geriatric Clear all
Active, not recruiting Not applicable Interventional

A Study of a Telemedicine Program for Older Adults With Cancer

NCT04917848
View directory record Official record
Conditions
Cancer
Interventions
Tele-Geriatric Oncology program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Results available

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

NCT02833857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

NCT05197075
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRV/COBI FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

NCT02669121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Great Lakes, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 16, 2026, 5:10 AM EDT
Suspended Phase 2 Interventional

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

NCT07547436
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
SAR445399, Placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Loxahatchee Groves, Florida • Plantation, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin

NCT07084116
View directory record Official record
Conditions
Skin Tear, Solar Purpura, Dermatoporosis
Interventions
Tretinoin 0.1% cream, Bland cream (non-drug)
Drug
Lead sponsor
James Thomas Pathoulas
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00224484
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141, Havrix (investigational formulation), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
5,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Results available

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

NCT05281601
View directory record Official record
Conditions
SARS-CoV-2
Interventions
AZD7442
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

NCT02187809
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clobazam
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
1 Year to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

NCT01379183
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

NCT02006537
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 16, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

NCT05304351
View directory record Official record
Conditions
Herpes Zoster, Shingles
Interventions
Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
50 Years and older
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
14
States / cities
Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

NCT00679835
View directory record Official record
Conditions
Gram Positive Infection, Concurrent Antibiotic Treatment
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 6 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 16, 2026, 5:10 AM EDT
Completed No phase listed Observational

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

NCT00973440
View directory record Official record
Conditions
Rectal Cancer, Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01364974
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K, Pharmacodynamics
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 16, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

NCT00358449
View directory record Official record
Conditions
Oesophagitis, Eosinophilic
Interventions
mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

NCT00707993
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 90 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Alexander City, Alabama • Foothill Ranch, California • Huntington Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

NCT06844214
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
SAR446268
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Gainesville, Florida • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

NCT04899336
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo
Biological · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
17,797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
142
States / cities
Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 5:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Flaus Electric Flosser on Plaque and Gingivitis Compared to a Manual Toothbrush

NCT07779564
View directory record Official record
Conditions
Gingivitis, Gingival Bleeding, Dental Plaque
Interventions
Electric Flosser, Manual Toothbrush
Device
Lead sponsor
Flaus, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 16, 2026, 5:10 AM EDT